SAB Biotherapeutics Warrant
SABSW
8 hedge funds and large institutions have $10.5K invested in SAB Biotherapeutics Warrant in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 6 → 8 (+2)
50% less capital invested
Capital invested by funds: $21.1K → $10.5K (-$10.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$401 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$45 |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$28 |
| 4 |
CS
Clear Street
New York
|
+$6 |
| 5 |
GS
GTS Securities
Miami,
Florida
|
+$6 |
Top Sellers
SABSW Hedge Fund Activity: Q2 2026 in Review
8 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q2 2026, worth a combined $10.5K — down 50% from $21.1K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SABSW positions and 0 closed out — a net gain of 2 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $401.
- 8 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q2 2026, up from 6 in Q1 2026.
- Funds reported $10.5K of SAB Biotherapeutics Warrant stock for Q2 2026, down 50% quarter-over-quarter.
- 2 funds opened new SAB Biotherapeutics Warrant positions in Q2 2026 and 0 closed out, a net change of +2 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q2 2026 was Virtu Financial, an estimated $401 added.
Based on aggregated 13F filings for Q2 2026.